This information paper is an evidence-based resource for primary care health professionals to help explain the latest treatment options for patients with severe asthma.
Four monoclonal antibody therapies (benralizumab, mepolizumab, dupilumab and omalizumab) are available in Australia for the treatment of severe asthma in patients whose asthma is uncontrolled despite optimised standard treatment.
Monoclonal antibody therapies are subsidised by the Pharmaceutical Benefits Scheme (PBS) for patients in specialist care who meet strict criteria.
The updated information paper and accompanying wall chart provide a clear and concise framework to help navigate this complex clinical area, including key practice points, information about use in pregnancy and ongoing care of patients receiving monoclonal antibody therapy.
Please download the information paper using the 'Download PDF' link on this page. Limited print copies are also available for health professionals by emailing [email protected].
Developed by the National Asthma Council Australia in collaboration with:
John Harrington, Respiratory clinical nurse consultant
Clinical Associate Professor Debbie Rigby, Advanced practice pharmacist
Dr Tom Skinner, Respiratory and sleep physician
Professor Peter Wark, Respiratory physician
This update has been developed independently by the National Asthma Council Australia with support from GlaxoSmithKline (GSK Australia) and Sanofi. Apart from providing a financial grant, GSK and Sanofi have not been involved in the development, recommendation, review or editing of this publication.
The first (2018) edition of this information paper was developed with support from GSK Australia.
National Asthma Council Australia. Monoclonal antibody therapy for severe asthma. National Asthma Council
Australia; Melbourne: 2025.
Although all care has been taken, this information is a general guide only, which is not a substitute for assessment of appropriate courses of treatment on a case-by-case basis. The National Asthma Council Australia expressly disclaims all responsibility (including for negligence) for any loss, damage or personal injury resulting from reliance on the information contained herein.
This chart lists the four available biologic treatments in Australia.
